EntreMed plans phase 2 trial of Panzem NCD in prostate cancer

By Lisa Kerner

Charlotte, N.C., Sept. 12 - EntreMed, Inc. began a multi-center phase 2 study to assess the anti-tumor activity, safety and pharmacokinetics of Panzem NCD (2-methoxyestradiol) in patients with hormone-refractory prostate cancer.

The study will be initially conducted by the University of Wisconsin's Comprehensive Cancer Center, with additional sites to be added during the third quarter.

"For this study, we chose to assess a valuable clinical endpoint (progression-free survival), as well as a pharmacodynamic endpoint using current imaging technology," principal investigator Glenn Liu said in a news release.

EntreMed is a clinical-stage pharmaceutical company located in Rockville, Md.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.